Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04700449 · ClinicalTrials.gov registry record · Phase 2
A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
A Phase 2 study, sponsored by Connect Biopharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
NCT04700449 is a Phase 2 study that has completed, run by Connect Biopharm. The registered enrollment target is 145 participants.
The verdict
NCT04700449, a Phase 2 study, has completed, sponsored by Connect Biopharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).
Interventions
- DRUG Double-Blind 0.2mg CBP-307
- DRUG Double-Blind Placebo
- DRUG Open-label CBP-307
- DRUG Double-Blind 0.1mg CBP-307
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2019-02-27 |
| Est. Completion | 2022-11-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04700449
The ClinicalTrials.gov registry entry for NCT04700449 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Connect Biopharm, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Double-Blind 0.2mg CBP-307 is the first listed.
NCT04700449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04700449 about?
NCT04700449 is a clinical study titled "A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)". This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).
What is the current status of trial NCT04700449?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2019-02-27. Estimated completion is 2022-11-10.
What interventions are being tested in trial NCT04700449?
The interventions under investigation include: Double-Blind 0.2mg CBP-307 (DRUG), Double-Blind Placebo (DRUG), Open-label CBP-307 (DRUG), Double-Blind 0.1mg CBP-307 (DRUG).
Who is sponsoring clinical trial NCT04700449?
This trial is sponsored by Connect Biopharm, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.